Surgery for hypertrophic cardiomyopathy

James J. Wu, Michael Seco, Caroline Medi, Chris Semsarian, David R. Richmond, Joseph A. Dearani, Hartzell V. Schaff, Michael J. Byrom, Paul G. Bannon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Hypertrophic cardiomyopathy (HCM) is a genetically determined cardiac disease characterised by otherwise unexplained myocardial hypertrophy of the left ventricle, and may result in left ventricular outflow tract obstruction. It is the most common cause of sudden cardiac death in young adults due to arrhythmias. Septal myectomy is a surgical treatment for HCM with moderate to severe outflow tract obstruction, and is indicated for patients with severe symptoms refractory to medical therapy. The surgical approach involves obtaining access to the interventricular septum via transaortic, transapical or transmitral approaches, and excising a portion of the hypertrophied myocardium to relieve the outflow tract obstruction. Large, contemporary series from centres experienced in septal myectomy patients have demonstrated a low early mortality of <2 %, excellent long-term survival that matches the general population, and durable relief of symptoms.

Original languageEnglish
Pages (from-to)117-125
Number of pages9
JournalBiophysical Reviews
Issue number1
Publication statusPublished - 2015
Externally publishedYes


  • Alcohol septal ablation
  • Hypertrophic cardiomyopathy
  • Left ventricular outflow tract obstruction
  • Septal myectomy


Dive into the research topics of 'Surgery for hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

Cite this